MA27664A1 - Acides gras a chaine moyenne, glycerides et analogues utilises en tant que stimulateurs de l'erythropoiese - Google Patents

Acides gras a chaine moyenne, glycerides et analogues utilises en tant que stimulateurs de l'erythropoiese

Info

Publication number
MA27664A1
MA27664A1 MA28479A MA28479A MA27664A1 MA 27664 A1 MA27664 A1 MA 27664A1 MA 28479 A MA28479 A MA 28479A MA 28479 A MA28479 A MA 28479A MA 27664 A1 MA27664 A1 MA 27664A1
Authority
MA
Morocco
Prior art keywords
erythroposis
stimulators
glycerides
fatty acids
chain fatty
Prior art date
Application number
MA28479A
Other languages
English (en)
Inventor
Christopher Penney
Lyne Gagnon
Pierre Laurin
Boulos Zacharie
Original Assignee
Prometic Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc filed Critical Prometic Biosciences Inc
Publication of MA27664A1 publication Critical patent/MA27664A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation d'une composition comprenant un composé représenté par la formule I, II, IIa, III ou IIIa; ou une combinaison de celles-ci, dans lesquelles chaque R1 représente indépendamment alkyle C7-11; A et B représentent indépendamment H ou CO-R1; R2 représente H ou alkyle C1-4; M représente un monocation (k=1) ou un dication (k=2) métallique ; Y vaut 0 ou NH; et Z vaut 0, NH, CH2O ou une liaison; pour la fabrication d'un médicament pour la stimulation de l'érythropoïèse. La composition comprend de préférence de l'érythropoïétine humaine.
MA28479A 2003-02-07 2005-09-05 Acides gras a chaine moyenne, glycerides et analogues utilises en tant que stimulateurs de l'erythropoiese MA27664A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44545403P 2003-02-07 2003-02-07

Publications (1)

Publication Number Publication Date
MA27664A1 true MA27664A1 (fr) 2005-12-01

Family

ID=32850990

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28479A MA27664A1 (fr) 2003-02-07 2005-09-05 Acides gras a chaine moyenne, glycerides et analogues utilises en tant que stimulateurs de l'erythropoiese

Country Status (28)

Country Link
US (1) US9682054B2 (fr)
EP (1) EP1592416B1 (fr)
JP (1) JP5390070B2 (fr)
KR (1) KR101120775B1 (fr)
CN (1) CN100427081C (fr)
AP (1) AP2005003367A0 (fr)
AR (1) AR043120A1 (fr)
AT (1) ATE419846T1 (fr)
AU (1) AU2004210193B2 (fr)
BR (1) BRPI0407276A (fr)
CA (1) CA2515160C (fr)
CY (1) CY1108963T1 (fr)
DE (2) DE04708802T1 (fr)
DK (1) DK1592416T3 (fr)
EA (1) EA009939B1 (fr)
ES (1) ES2255467T3 (fr)
IL (1) IL170057A (fr)
JO (1) JO2705B1 (fr)
MA (1) MA27664A1 (fr)
MX (1) MXPA05008382A (fr)
MY (1) MY140913A (fr)
NO (1) NO334085B1 (fr)
NZ (1) NZ541593A (fr)
PT (1) PT1592416E (fr)
SI (1) SI1592416T1 (fr)
TN (1) TNSN05189A1 (fr)
WO (1) WO2004069237A1 (fr)
ZA (1) ZA200506246B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0208984A (pt) 2001-04-18 2004-06-29 Prometic Biosciences Inc ácidos graxos, glicerìdeos e análogos de comprimento de cadeia médio como fatores de sobrevivência e ativação de neutrófilos
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
MXPA06011871A (es) * 2004-04-15 2007-10-08 Chiasma Inc Composiciones capaces de facilitar la penetracion a traves de una barrera biologica.
ES2561048T3 (es) 2004-07-23 2016-02-24 Acceleron Pharma Inc. Polipéptidos del receptor ActRII
AU2005279614A1 (en) * 2004-09-03 2006-03-09 Prometic Biosciences Inc. Substituted purinyl derivatives with immunomodulator and chemoprotective activity and use alone or with medium-chain length fatty acids or glycerides
PT1804780E (pt) * 2004-10-01 2012-01-19 Prometic Biosciences Inc Álcoois gordos com comprimento médio da cadeia como estimuladores da hematopoiese
US8071580B2 (en) 2004-10-01 2011-12-06 Prometic Biosciences Inc. Medium-chain length fatty alcohols as stimulators of hematopoiesis
ME00380B (fr) 2005-11-23 2011-10-10 Acceleron Pharma Inc Antagonistes de l'activine-actriia et utilisations pour activer la croissance osseuse
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US9526759B2 (en) 2007-02-01 2016-12-27 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
KR101672156B1 (ko) 2007-02-09 2016-11-02 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
CN107412734A (zh) 2007-09-18 2017-12-01 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
MX338513B (es) 2007-11-02 2016-04-20 Prometic Pharma Smt Ltd Acidos grasos de longitud de cadena mediana y gliceridos como agentes de nefroprotección.
CA2708679C (fr) * 2007-12-19 2016-11-15 Prometic Biosciences Inc. Acides gras, sels et triglycerides a longueur de chaine moyenne combines avec de la gemcitabine, destines au traitement du cancer du pancreas
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
LT3750552T (lt) 2008-08-14 2023-06-26 Acceleron Pharma Inc. Gdf gaudyklės
NZ591810A (en) 2008-09-17 2012-12-21 Chiasma Inc Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
MX385318B (es) 2009-06-08 2025-03-18 Acceleron Pharma Inc Metodos para aumentar adipocitos termogenicos.
JP2012529294A (ja) 2009-06-12 2012-11-22 アクセルロン ファーマ， インコーポレイテッド 切断型ＡｃｔＲＩＩＢ−Ｆｃ融合タンパク質
CA2770822C (fr) * 2009-08-13 2020-03-24 Acceleron Pharma Inc. Utilisation combinee de pieges gdf et d'activateurs du recepteur de l'erythropoietine pour augmenter les taux de globules rouges
EP2501400B1 (fr) 2009-11-17 2017-11-01 Acceleron Pharma, Inc. Protéines actriib et variants et utilisations de celles-ci se rapportant à l'induction de l'utrophine pour une thérapie de la dystrophie musculaire
WO2012064771A1 (fr) 2010-11-08 2012-05-18 Acceleron Pharma, Inc. Agents de liaison à actriia et leurs utilisations
TWI572352B (zh) * 2012-03-01 2017-03-01 波麥堤克藥學Ｓｍｔ有限公司 用於製備具中鏈長度之脂肪酸的三酸甘油酯之方法
RU2018145985A (ru) 2012-11-02 2019-02-18 Селджин Корпорейшн Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
CN102973922B (zh) * 2012-12-18 2016-02-03 华东理工大学 一种融合蛋白的应用
TN2016000553A1 (en) 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
DK3227675T3 (da) 2014-12-03 2023-05-30 Celgene Corp Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom
PL3253401T3 (pl) 2015-02-03 2025-08-04 Amryt Endo, Inc. Leczenie akromegalii oktreotydem doustnym
US20170021029A1 (en) * 2015-04-15 2017-01-26 Jeffrey Charles Raber Topical formulations and uses
SG11202103011YA (en) 2018-10-11 2021-04-29 Basf As Aromatic compounds and pharmaceutical uses thereof
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871768A (en) 1984-07-12 1989-10-03 New England Deaconess Hospital Corporation Dietary supplement utilizing ω-3/medium chain trigylceride mixtures
US7307166B1 (en) 1987-10-28 2007-12-11 Wellstat Therapeutics Corporation Oxpurine nucleosides and their congeners, and acyl, derivatives thereof, for improvement of hematopoiesis
US5011852A (en) 1988-07-25 1991-04-30 Applied Analytical Industries, Inc. Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
JP3014119B2 (ja) * 1990-05-28 2000-02-28 雪印乳業株式会社 直腸投与用赤血球造血剤
JP3249147B2 (ja) 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
DK0495187T3 (da) * 1991-01-15 1997-08-11 Hemosphere Inc Protein-nanomatricer og fremstillingsmetode.
JPH05163160A (ja) 1991-12-13 1993-06-29 Snow Brand Milk Prod Co Ltd 免疫低下に伴う感染症の予防及び治療用栄養剤
US5214035A (en) 1992-04-16 1993-05-25 Hoechst-Roussel Agri-Vet Company Thixotropic formulations
US5318781A (en) * 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
US20010003739A1 (en) * 1993-06-24 2001-06-14 Astrazeneca Ab Systemic administration of a therapeutic preparation
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
AU7082694A (en) * 1994-05-10 1995-11-29 Kitasato Institute, The Hematopoietic stem cell proliferation accelerator
US5470861A (en) 1994-08-04 1995-11-28 Hoffmann-La Roche Inc. Method of promoting hair growth
US5549905A (en) 1994-10-18 1996-08-27 Clintec Nutrition Co. Enternal composition for pediatric patients
IT1275802B1 (it) 1994-11-03 1997-10-17 Hoffmann La Roche Composizione di interferone
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
AUPN933396A0 (en) 1996-04-17 1996-05-09 Pfizer Pty Limited Non-aqueuos oral-drench compositions containing avermectin compounds
US5851534A (en) 1996-05-03 1998-12-22 Dynagen, Inc. Methods for prevention and/or treatment of neutropenia
JPH10265380A (ja) 1997-03-17 1998-10-06 Bristol Myers Squibb Co 抗ガン剤
US6726924B2 (en) * 1997-09-04 2004-04-27 Biozone Laboratories, Inc. Oral liposomal delivery system
ATE554748T1 (de) * 1997-11-14 2012-05-15 Pacira Pharmaceuticals Inc Herstellung von multivesikulären liposomen
CA2311124A1 (fr) 1997-11-19 1999-05-27 Hercules Incorporated Suspensions polymeriques fluidifees de polysaccharides cationiques dans des emollients et leur emploi dans la preparation de compositions pour soins d'hygiene corporelle
WO1999026640A1 (fr) 1997-11-20 1999-06-03 Bukwang Pharm. Ind. Co., Ltd. Composition pharmaceutique contenant des extraits de bois de cervus nippon possedant une activite de stimulation de la croissance des cellules souches hematopoietiques et des megacaryocytes
DE69825137T2 (de) * 1998-02-23 2005-07-21 Cilag Ag International Liposomale Erythropoietin-Dispersion
DK1062952T3 (da) 1998-03-11 2003-11-24 Grelan Pharmaceutical Co Brusende enteropræparater
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
AU7719100A (en) 1999-09-27 2001-04-30 Panayiotis Constantinides Compositions of tocol-soluble therapeutics
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
DE60123603T2 (de) 2000-06-14 2007-08-16 William Leslie Diss Porter Lipide zur änderung des abwehrsystems
US6967028B2 (en) 2000-07-31 2005-11-22 Mainelab Prolonged release microspheres for injectable administration
IL142535A0 (en) 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
BR0208984A (pt) * 2001-04-18 2004-06-29 Prometic Biosciences Inc ácidos graxos, glicerìdeos e análogos de comprimento de cadeia médio como fatores de sobrevivência e ativação de neutrófilos
US20040052836A1 (en) 2002-09-13 2004-03-18 Li Luk Chiu Pharmaceutical compositions containing at least one stable liposphere having an improved shelf life
US6725510B1 (en) 2003-04-25 2004-04-27 Almetta Clyburn Inclining coffin
AU2004261461B2 (en) 2003-07-25 2008-12-18 Prometic Pharma Smt Limited Preparation of metal salts of medium-chain fatty acids
AU2005279614A1 (en) 2004-09-03 2006-03-09 Prometic Biosciences Inc. Substituted purinyl derivatives with immunomodulator and chemoprotective activity and use alone or with medium-chain length fatty acids or glycerides
US8071580B2 (en) 2004-10-01 2011-12-06 Prometic Biosciences Inc. Medium-chain length fatty alcohols as stimulators of hematopoiesis

Also Published As

Publication number Publication date
US20060128800A1 (en) 2006-06-15
NO20053994L (no) 2005-10-06
JO2705B1 (ar) 2014-03-15
AU2004210193B2 (en) 2007-07-12
EA200501267A1 (ru) 2006-02-24
PT1592416E (pt) 2009-04-03
DK1592416T3 (da) 2009-04-20
CN100427081C (zh) 2008-10-22
AP2005003367A0 (en) 2005-09-30
US9682054B2 (en) 2017-06-20
TNSN05189A1 (en) 2007-06-11
CN1753665A (zh) 2006-03-29
MY140913A (en) 2010-01-29
ES2255467T3 (es) 2009-05-01
CA2515160A1 (fr) 2004-08-19
DE602004018902D1 (de) 2009-02-26
NZ541593A (en) 2009-05-31
JP5390070B2 (ja) 2014-01-15
KR20050118671A (ko) 2005-12-19
NO20053994D0 (no) 2005-08-26
WO2004069237A1 (fr) 2004-08-19
JP2006516987A (ja) 2006-07-13
DE04708802T1 (de) 2006-06-22
IL170057A (en) 2011-09-27
MXPA05008382A (es) 2005-11-04
BRPI0407276A (pt) 2006-01-31
EA009939B1 (ru) 2008-04-28
EP1592416A1 (fr) 2005-11-09
SI1592416T1 (sl) 2009-06-30
AR043120A1 (es) 2005-07-20
CA2515160C (fr) 2013-01-08
CY1108963T1 (el) 2014-07-02
ZA200506246B (en) 2006-12-27
EP1592416B1 (fr) 2009-01-07
NO334085B1 (no) 2013-12-09
ATE419846T1 (de) 2009-01-15
ES2255467T1 (es) 2006-07-01
KR101120775B1 (ko) 2012-04-18
AU2004210193A1 (en) 2004-08-19

Similar Documents

Publication Publication Date Title
MA27664A1 (fr) Acides gras a chaine moyenne, glycerides et analogues utilises en tant que stimulateurs de l'erythropoiese
ATE311188T1 (de) Kombination eines angiotensin-ii antagonistisch wirkenden benzimidazols mit manidipin zur behandlung von bluthochdruck
CU22305A3 (es) Procedimiento para la preparacion de un derivado de aminoacidos
NO2011026I2 (no) Eribulin eller et farmasøytisk akseptabelt salt derav
ATE260255T1 (de) 5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate
ATE216384T1 (de) Thiazolylbenzofuranderivate und pharmazeutische zusammensetzungen die sie enthalten
CY1111843T1 (el) 2-υποκατεστημενα αναλογα βιταμινης d και θεραπευτικες χρησεις αυτων
ATE105556T1 (de) Benzopyranverbindungen, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen.
DE68906609D1 (de) Dopamin-vorlaeufer.
EA200000431A2 (ru) Новые замещенные димерные соединения, способ их получения и фармацевтические композиции, содержащие их
MX9206093A (es) Derivado de oxazolidona
BRPI0413791A (pt) composto, método para o tratamento de um indivìduo humano ou animal que sofre de, ou que é suscetìvel a um distúrbio auto-imune ou uma condição inflamatória, uso de um composto, composição farmacêutica, e, processo para a prearação de compostos
AR029468A1 (es) Derivados de aminoacidos n-mercaptoacilados, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
KR970703301A (ko) 신규 디아미노메틸리덴 유도체(novel diamincmethylidene derivative)
DE69911557D1 (de) Imidazoline Derivate,ihre Herstellung und pharmazeutische Zusammensetzungen die sie enthalten
KR950701329A (ko) 벤조티아졸술폰아미드 유도체, 그의 제조법 및 그 용도(Benzothiazolesulfornamide derivative, method for preparing the same, and use thereof)
KR950702544A (ko) 비페닐메탄 유도체 및 이를 함유하는 약제
EA200400756A1 (ru) Новые соединения бензотиазина и бензотиадиазина, способ их получения и фармацевтические композиции, которые их содержат
PL211567A1 (pl) Sposob wytwarzania zwiazku optycznie czynnego
DE69914563D1 (de) Azaindol derivate und ihre Verwendung als antithrombotische Wirkstoffe
ES2143159T3 (es) Nuevos derivados de 2-ciano-3-hidroxi-propenamidas que comprenden un radical trifluorometilsulfonilfenilo/trifluorometilsulfinilfenilo, procedimiento de preparacion, aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
DE3871160D1 (de) Prostaglandinderivate, verfahren zu ihrer herstellung und ihre pharmazeutische anwendung.
DE68909961D1 (de) 2-Aminoacetamid Derivate.
DE69407227D1 (de) Die Verwendung von 2-Phenylmethylene-1-3'-(amino)-2-(hydroxy)-propoxy-imino-cyclohexane-Derivaten
ATE87004T1 (de) Fluor enthaltende makrolid-verbindungen, pharmazeutische zusammensetzungen, welche diese enthalten und ihre verwendung fuer die herstellung von arzneimitteln.